Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003;16(4):389-95.
doi: 10.1159/000072562.

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

Peirre Amarenco, Julien Bogousslavsky, Alfred S Callahan, Larry Goldstein, Michael Hennerici, Henrik Sillsen, Michael A Welch, Justin Zivin; SPARCL Investigators
Clinical Trial

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

Peirre Amarenco et al. Cerebrovasc Dis. 2003.

Erratum in

  • Cerebrovasc Dis. 2004;17(1):91-2

Abstract

Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention.

PubMed Disclaimer

Publication types

MeSH terms